Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568023 | 1.00 | MAPT (0.53) | MAPTMMP2ANPEPALDH1A1SMN1; SMN2 | |
| SCHEMBL5653777 | 0.86 | MAPT (0.56) | MAPTALDH1A1SMN1; SMN2RXFP1GAA | |
| SCHEMBL5653056 | 0.84 | GAA (0.54) | MAPTMMP2ALDH1A1GAA | |
| SCHEMBL14367284 | 0.84 | GAA (0.54) | MAPTMMP2ALDH1A1GAA | |
| SCHEMBL3885054 | 0.78 | MAPT (0.61) | MAPTMMP2ANPEPALDH1A1SMN1; SMN2 | |
| SCHEMBL28547111 | 0.78 | MMP2 (0.45) | MAPTMMP2ANPEPALDH1A1SMN1; SMN2 | |
| SCHEMBL28543125 | 0.78 | MMP2 (0.45) | MAPTMMP2ANPEPALDH1A1SMN1; SMN2 | |
| SCHEMBL28543121 | 0.78 | MMP2 (0.45) | MAPTMMP2ANPEPALDH1A1SMN1; SMN2 | |
| SCHEMBL7968279 | 0.78 | GAA (0.43) | MAPTMMP2ANPEPALDH1A1GAA | |
| SCHEMBL7985048 | 0.78 | GAA (0.43) | MAPTMMP2ANPEPALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MAPT 855/4885MMP2 2953/4885ANPEP 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.